CG Oncology’s Post

Join me and my panel of experts next week at the #SCRS Diversity and Oncology Summits! Our topic will be: Best Practices For Streamlined Budget Negotiations & Approvals. See you there!

Less than 100 days and counting! The 2024 Conference equips every attendee with new ideas and relationships that advance community oncology. Regardless of your role, the Conference provides attendees a blueprint to bring back to your practice of how to drive your practice forward. I’m looking forward to a robust discussion with my fellow panelists during our session Revenue Cycle Management Success in Community Oncology: Measurement & Dashboards and learning new strategies that I can apply in my practice. #COA2024 #StrongerTogether

Come hear C. K. Wang and Wendy Turenne talk oncology RWD at #ISPORAnnual and stay for a demo of COTA's data on the Aetion Evidence Platform!

Dr. Vernon Sondak shares his insights on the data he's most excited about coming up at #ESMO24 which includes developments in #CellularTherapies as well as #Immunotherapy. What data are you looking forward to? __________________________________________________________________ 🔬 Don't miss out on the latest developments in oncology! Let us show you how we can get the insights you need, from the HCPs you want to hear from - even during busy congress season! #ClinicalTrials #MetastaticDisease

Are you a leader at a patient organization? If so, you won’t want to miss the third installment of our five-part Patient Organization Webinar Series. Join fellow leaders for Changing Oncology Landscape: Considerations for Oncology Organizations and Registries. 📅 Wednesday, June 26, 2024, 11:00 AM EDT 📌 Webinar 🎙️ Audra Moran, Kapila Viges, Jeff Hodge, Murray Aitken 🔗 Register here: https://lnkd.in/ehRnEdkj #PatientAdvocacy #PatientOutcomes

Don’t miss our upcoming webinar on Harnessing Real-World Data for Market Access Success!   Hear from WEP's Senior Market Access Leadership Team about the transformative impact of Real World Data (RWD) in rare diseases, oncology, and advanced therapies.   Dive deep into live examples of how RWD has supported market access outcomes and learn best practices for conducting an effective RWD study.   Click the link below to register:   https://lnkd.in/dpraFQFn   We are really looking forward to sharing our expertise!  #RealWorldData #MarketAccess #WithEveryPatient

This is an excellent piece of work from Georgia, linking real world oncology data, chemotherapy regimes and outcomes for 15000 patients from #NDRS National cancer register in England. The inference of disease free survival is a significant step in large scale datasets. If you are in Basel, definitely one to check out and really exemplifing the novel thought leadership in oncology at Genomics England Matthew Brown Richard Scott Emma McCargow #cancer #realworlddata #bigdata #ndrs #ncras

Your clinical oncology data has untapped potential to help advance patient care and unlock new research opportunities. In this webinar, Q-Centrix's Vice President, Oncology Market Lead Karen Schmidt, ODS, Senior Vice President of Data and Research Victor Wang, and Director of Research Kate Sheeran, MSN, AGPCNP-BC, explore how clinical data intersects with research study data. Transform your registry data from a perceived cost center to an asset with infinite possibilities—by taking this opportunity to see clinical data differently!📲 https://lnkd.in/g-TzGaY5 . #SeeItDifferently #ClinicalResearch #ClinicalDataManagement

Collaborations between academic centers and pharmaceutical companies like AstraZeneca represent a powerful synergy that accelerates the translation of cutting-edge research into tangible medical advancements. These partnerships leverage the unique strengths of both sectors: academic institutions provide innovative, high-risk research ideas and deep scientific expertise, while pharmaceutical companies offer substantial resources, infrastructure, and the capability to scale discoveries into clinical applications. For instance, through such collaborations, novel drug candidates can progress from early-stage research to clinical trials more efficiently, benefiting from the rigorous scientific validation and extensive testing provided by both parties. These alliances also foster a dynamic exchange of knowledge and expertise, enhancing the pipeline of new therapies and ultimately improving patient outcomes. By aligning academic curiosity with industry resources, these collaborations play a crucial role in addressing unmet medical needs and pushing the boundaries of science. Proud to be included in our partnership with AZ. #sciencefirst #partnerships

It's not to late to join the conversation! Register now for this week's webinar to hear from oncology clinical trial patient Mike Herman, patient advocate and founder of Speaking On Cancer Patient Advocacy. You’ll also here more on: 🔍The Site's Lens: Amy Avergas MSIT, MBA, Manager of Oncology Research at Medstar Health Research Institute, will share her insights into how Greenphire's participant payment solution, ClinCard, is changing the game for patients and research sites alike. 💡 Technology Enablement: Meet Greenphire's very own PhDs on staff, Michael Rogan, PhD, LCSW and Clay Williams, creators of GreenSpace. Discover how this patient-powered registry, utilized by organizations like MBCA, is shaping the future of oncology research. It's no secret that there are significant gaps in the patient journey. That’s why we are on a mission to bridge them. Don't miss out - register today! https://lnkd.in/eVTDtyCc